TY - JOUR
T1 - CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
AU - Shree, Tanaya
AU - Shankar, Vishnu
AU - Lohmeyer, Julian J.K.
AU - Czerwinski, Debra K.
AU - Schroers-Martin, Joseph G.
AU - Rodriguez, Gladys M.
AU - Beygi, Sara
AU - Kanegai, Alyssa M.
AU - Corbelli, Karen S.
AU - Gabriel, Etelka
AU - Kurtz, David M.
AU - Khodadoust, Michael S.
AU - Gupta, Neel K.
AU - Maeda, Lauren S.
AU - Advani, Ranjana H.
AU - Alizadeh, Ash A.
AU - Levy, Ronald
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients with lymphoma, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies postvaccination, compared with 100% of controls. When evaluating patients last treated from days to nearly 18 years prior to vaccination, time since last anti-CD20 was a significant independent predictor of vaccine response. None of 31 patients who had received anti-CD20 treatment within 6 months prior to vaccination developed blocking antibodies. In contrast, patients who initiated anti-CD20 treatment shortly after achieving a vaccine-induced antibody response tended to retain that response during treatment, suggesting a policy of immunizing prior to treatment whenever possible.
AB - To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients with lymphoma, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies postvaccination, compared with 100% of controls. When evaluating patients last treated from days to nearly 18 years prior to vaccination, time since last anti-CD20 was a significant independent predictor of vaccine response. None of 31 patients who had received anti-CD20 treatment within 6 months prior to vaccination developed blocking antibodies. In contrast, patients who initiated anti-CD20 treatment shortly after achieving a vaccine-induced antibody response tended to retain that response during treatment, suggesting a policy of immunizing prior to treatment whenever possible.
UR - http://www.scopus.com/inward/record.url?scp=85123685850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123685850&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-21-0222
DO - 10.1158/2643-3230.BCD-21-0222
M3 - Article
C2 - 35015688
AN - SCOPUS:85123685850
SN - 2643-3230
VL - 3
SP - 95
EP - 102
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 2
ER -